Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients

por Xiong, Anning, Nie, Wei, Zhou, Yan, Li, Changhui, Gu, Kai, Zhang, Ding, Chen, Shiqing, Wen, Fengcai, Zhong, Hua, Han, Baohui, Zhang, Xueyan
Publicado 2021

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer

por Xiong, Anning, Xu, Jianlin, Wang, Shuyuan, Zhong, Runbo, Lu, Jun, Chu, Tianqing, Zhang, Wei, Li, Ying, Zheng, Xiaoxuan, Han, Baohui, Nie, Wei, Zhong, Hua, Zhang, Xueyan
Publicado 2023

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

por Xiong, Anning, Nie, Wei, Cheng, Lei, Zhong, Hua, Chu, Tianqing, Zhong, Runbo, Lu, Jun, Wang, Shuyuan, Xu, Jianlin, Shen, Yinchen, Pan, Feng, Han, Baohui, Zhang, Xueyan
Publicado 2022

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

por Li, Changhui, Nie, Wei, Guo, Jingdong, Xiong, Anning, Zhong, Hua, Chu, Tianqing, Zhong, Runbo, Xu, Jianlin, Lu, Jun, Zheng, Xiaoxuan, Zhang, Bo, Shen, Yinchen, Pan, Feng, Han, Baohui, Zhang, Xueyan
Publicado 2021

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer

por Zheng, Liang, Xiong, Anning, Wang, Shuyuan, Xu, Jianlin, Shen, Yinchen, Zhong, Runbo, Lu, Jun, Chu, Tianqing, Zhang, Wei, Li, Ying, Zheng, Xiaoxuan, Han, Baohui, Zhong, Hua, Nie, Wei, Zhang, Xueyan
Publicado 2023